Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 10.62B 9.29B 8.57B 7.93B 15.05B 1,014B 15.3B 103B 40.22B 498B 39.87B 39.01B 1,725B P/E 2026 *
-17.8x
P/E 2027 * -39.2x
Enterprise Value 10.37B 9.07B 8.36B 7.74B 14.69B 990B 14.94B 100B 39.27B 486B 38.93B 38.08B 1,684B EV / Sales 2026 *
11.6x
EV / Sales 2027 * 7.28x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-23.90%
1 week-21.43%
Current month-18.94%
1 month-13.82%
3 months-15.91%
6 months-19.96%
Current year-18.76%
1 week 64.1
Extreme 64.1001
86.74
1 month 64.1
Extreme 64.1001
86.74
Current year 64.1
Extreme 64.1001
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-23.90%-21.43%+50.06%+53.83% 10.62B
+0.89%+2.47%+3.34%+11.31% 50.44B
+0.72%+1.00%+396.18%+624.25% 40.63B
+2.54%+0.93%+28.98%-3.62% 34.88B
+0.31%+1.74%+18.44%+59.76% 33.67B
-2.09%-1.98%+3.21%+33.56% 26.29B
-0.63%+0.34% - - 17.11B
+0.66%-3.96%+66.85%+127.36% 15.29B
+0.93%+0.14%+14.58%+21.99% 13.74B
+1.99%-2.48%+12.12%-28.62% 12.93B
Average -1.86%-2.69%+65.97%+99.98% 25.56B
Weighted average by Cap. -0.38%-0.70%+83.41%+130.64%

Financials

2026 *2027 *
Net sales 892M 780M 719M 665M 1.26B 85.1B 1.28B 8.61B 3.38B 41.79B 3.35B 3.27B 145B 1.45B 1.27B 1.17B 1.08B 2.05B 138B 2.08B 13.98B 5.48B 67.82B 5.43B 5.31B 235B
Net income -606M -530M -489M -452M -858M -57.83B -873M -5.85B -2.29B -28.4B -2.27B -2.23B -98.37B -232M -203M -187M -173M -329M -22.15B -334M -2.24B -879M -10.88B -871M -852M -37.67B
Net Debt -252M -221M -204M -188M -358M -24.1B -364M -2.44B -956M -11.83B -948M -927M -40.99B -86.16M -75.37M -69.5M -64.31M -122M -8.22B -124M -832M -326M -4.04B -323M -316M -13.99B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-09 US$64.27 -23.90% 20,447,626
26-07-08 US$84.46 -2.17% 2,280,833
26-07-07 US$86.33 +3.79% 2,646,707
26-07-06 US$83.18 +1.69% 1,847,437
26-07-02 US$81.80 +3.30% 2,301,899
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
64.27USD
Average target price
98.27USD
Spread / Average Target
+52.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock